CA2694983A1 - Traitements de troubles proliferatifs des lymphocytes b - Google Patents

Traitements de troubles proliferatifs des lymphocytes b Download PDF

Info

Publication number
CA2694983A1
CA2694983A1 CA2694983A CA2694983A CA2694983A1 CA 2694983 A1 CA2694983 A1 CA 2694983A1 CA 2694983 A CA2694983 A CA 2694983A CA 2694983 A CA2694983 A CA 2694983A CA 2694983 A1 CA2694983 A1 CA 2694983A1
Authority
CA
Canada
Prior art keywords
inhibitors
pde
cell proliferative
proliferative disorder
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2694983A
Other languages
English (en)
Inventor
Richard Rickles
Margaret S. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
Combinatorx, Incorporated
Richard Rickles
Margaret S. Lee
Zalicus Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx, Incorporated, Richard Rickles, Margaret S. Lee, Zalicus Inc. filed Critical Combinatorx, Incorporated
Publication of CA2694983A1 publication Critical patent/CA2694983A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2694983A 2007-07-17 2008-07-17 Traitements de troubles proliferatifs des lymphocytes b Abandoned CA2694983A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95030707P 2007-07-17 2007-07-17
US60/950,307 2007-07-17
US96558707P 2007-08-21 2007-08-21
US60/965,587 2007-08-21
PCT/US2008/008758 WO2009011893A2 (fr) 2007-07-17 2008-07-17 Traitements de troubles prolifératifs des lymphocytes b

Publications (1)

Publication Number Publication Date
CA2694983A1 true CA2694983A1 (fr) 2009-01-22

Family

ID=40260271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2694983A Abandoned CA2694983A1 (fr) 2007-07-17 2008-07-17 Traitements de troubles proliferatifs des lymphocytes b

Country Status (8)

Country Link
US (1) US20090053168A1 (fr)
EP (1) EP2178369A4 (fr)
AU (1) AU2008276451A1 (fr)
BR (1) BRPI0813516A2 (fr)
CA (1) CA2694983A1 (fr)
EA (1) EA201000219A1 (fr)
TW (1) TW200920381A (fr)
WO (1) WO2009011893A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2009157938A1 (fr) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. Antagonistes de récepteur d’adénosine a2b pour traiter le cancer
NZ590489A (en) 2008-07-03 2013-01-25 Univ Virginia Patent Found Unit dosage of apadenoson
BRPI0918407A2 (pt) * 2008-08-20 2015-11-24 Ziopharm Oncology Inc compostos organoarsênicos e métodos para o tratamento de câncer
BRPI1012770B8 (pt) 2009-05-14 2021-05-25 Tianjin Hemay Bio Tech Co Ltd derivados de tiofeno
RU2577541C2 (ru) * 2010-08-09 2016-03-20 ВЕРОНА ФАРМА ПиЛСи КРИСТАЛЛИЧЕСКАЯ ФОРМА СОЕДИНЕНИЯ ПИРИМИДО [6, 1-а]ИЗОХИНОЛИН-4-ОНА
JP5835729B2 (ja) * 2010-09-02 2015-12-24 国立大学法人京都大学 筋萎縮性側索硬化症の予防および治療用医薬組成物
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
WO2014142220A1 (fr) * 2013-03-13 2014-09-18 アステラス製薬株式会社 Agent antitumoral
US9314460B1 (en) * 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
US20160304546A1 (en) * 2013-12-05 2016-10-20 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
PL408251A1 (pl) * 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US20240101699A1 (en) * 2021-01-07 2024-03-28 The Regents Of The University Of California Modulation of cd46 cell surface expression and therapeutic use thereof
WO2022150512A1 (fr) * 2021-01-07 2022-07-14 The Regents Of The University Of California Modulation du marqueur de surface cellulaire cd46 dans les cellules cancéreuses positives et négatives du récepteur des androgènes
CN112939996B (zh) * 2021-02-01 2022-04-26 湖南文理学院 一种以n-氧化吡啶衍生物为识别基团的近红外荧光探针化合物及其制备和应用
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5925682A (en) * 1995-11-20 1999-07-20 Immunotech Inc. Epinephrine as inhibitor of cancerous tumors
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
AU6047099A (en) * 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
EP1379275A4 (fr) * 2001-03-14 2005-12-21 Centocor Inc Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003294312A1 (en) * 2002-11-18 2004-07-09 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2512819A1 (fr) * 2003-01-14 2004-07-29 Altana Pharma Ag Inhibiteurs de pde4 pour le traitement de neoplasmes de cellules lymphoides
PT2298743E (pt) * 2003-06-26 2012-12-04 Novartis Ag Inibidores de p38 quinase a base de heterociclo de 5 elementos
AU2004261589B2 (en) * 2003-07-25 2008-05-22 Novartis Ag p-38 kinase inhibitors
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1799673A1 (fr) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Derives de pyrazole utilises en tant qu'inhibiteurs de phosphodiesterase 4
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
WO2007087367A2 (fr) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Procédés et compositions pour la modulation de la mobilisation de cellules souches
WO2007100895A2 (fr) * 2006-02-27 2007-09-07 The Johns Hopkins University Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
WO2008023362A2 (fr) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Traitement du cancer
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
TW200920381A (en) 2009-05-16
WO2009011893A3 (fr) 2009-03-19
BRPI0813516A2 (pt) 2014-12-30
EA201000219A1 (ru) 2010-12-30
AU2008276451A1 (en) 2009-01-22
EP2178369A4 (fr) 2010-12-15
US20090053168A1 (en) 2009-02-26
EP2178369A2 (fr) 2010-04-28
WO2009011893A2 (fr) 2009-01-22

Similar Documents

Publication Publication Date Title
US20090053168A1 (en) Treatments of b-cell proliferative disorders
US20090047243A1 (en) Combinations for the treatment of b-cell proliferative disorders
US20100009934A1 (en) Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
CN110621316B (zh) 用ehmt2抑制剂进行的组合疗法
AU2017372856B9 (en) Preservation of immune response during chemotherapy regimens
TWI689307B (zh) 經取代之2,3-二氫咪唑并[1,2-c]喹唑啉之用途
CA2450777C (fr) Utilisation d'inhibiteurs c-src seuls ou en combinaison avec sti571 pour le traitement de leucemies
AU2013257951A1 (en) Use of compounds for the treatment of pain
US20160220569A1 (en) CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CN112472699A (zh) 改善比生群及衍生物的治疗益处的组合方法
CN106456777A (zh) 结合物
JP2007522200A (ja) 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ
KR20150079745A (ko) Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
MXPA01003855A (es) Combinaciones de antagonistas del factor de liberacion de corticotropina y secretagogos de hormona del crecimiento.
KR101292508B1 (ko) 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
TWI233359B (en) Pharmaceutical composition for treating neoplasm
KR20060037252A (ko) 불안 장애의 치료 방법
KR20200119800A (ko) 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
NZ795224A (en) Preservation of immune response during chemotherapy regimens
MXPA06009271A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2003063988A (ja) Ｐｄｅ阻害剤を有効成分として含有する脊髄小脳変性症治療剤

Legal Events

Date Code Title Description
FZDE Dead